Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling.

Best M, Newson AJ, Meiser B, Juraskova I, Goldstein D, Tucker K, Ballinger ML, Hess D, Schlub TE, Biesecker B, Vines R, Vines K, Thomas D, Young MA, Savard J, Jacobs C, Butow P.

BMC Cancer. 2018 Apr 5;18(1):389. doi: 10.1186/s12885-018-4310-0.

2.

Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk.

Willis AM, Smith SK, Meiser B, Ballinger ML, Thomas DM, Tattersall M; International Sarcoma Kindred Study (ISKS); Kathleen Cuningham National Consortium for Research into Familial Breast Cancer (kConFab), Young MA.

J Genet Couns. 2018 Feb 17. doi: 10.1007/s10897-018-0223-y. [Epub ahead of print]

PMID:
29455319
3.

Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Lecanda F, Serra M, Hattinger C, Picci P, Scotlandi K, Thomas DM, Ballinger ML, Gorlick R, Barkauskas DA, Spector LG, Tucker M, Belynda DH, Yeager M, Hoover RN, Wacholder S, Chanock SJ, Savage SA, Mirabello L.

Int J Cancer. 2018 Apr 15;142(8):1594-1601. doi: 10.1002/ijc.31195. Epub 2017 Dec 23.

PMID:
29210060
4.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA.

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968.

PMID:
28772291
5.

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.

Ballinger ML, Ferris NJ, Moodie K, Mitchell G, Shanley S, James PA, Thomas DM.

JAMA Oncol. 2017 Dec 1;3(12):1735-1736. doi: 10.1001/jamaoncol.2017.1355. No abstract available.

PMID:
28772290
6.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

7.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

PMID:
28137790
8.

Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

McBride KA, Ballinger ML, Schlub TE, Young MA, Tattersall MHN, Kirk J, Eeles R, Killick E, Walker LG, Shanley S, Thomas DM, Mitchell G.

Fam Cancer. 2017 Jul;16(3):423-432. doi: 10.1007/s10689-016-9964-7.

PMID:
28124295
9.

Sarcoma and germ-line DICER1 mutations - Authors' reply.

Ballinger ML, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Nov;17(11):e471. doi: 10.1016/S1470-2045(16)30527-7. No abstract available.

PMID:
27819238
10.

Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review.

Willis AM, Smith SK, Meiser B, Ballinger ML, Thomas DM, Young MA.

Clin Genet. 2017 Aug;92(2):121-133. doi: 10.1111/cge.12868. Epub 2016 Oct 23. Review.

PMID:
27643459
11.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
12.

Diagnosis and Management of Hereditary Sarcoma.

Thomas DM, Ballinger ML.

Recent Results Cancer Res. 2016;205:169-89. doi: 10.1007/978-3-319-29998-3_10.

PMID:
27075354
13.

International survey of awareness of genetic risk in the clinical sarcoma community.

McBride KA, Schlub TE, Ballinger ML, Thomas DM, Tattersall MH.

Asia Pac J Clin Oncol. 2016 Jun;12(2):133-42. doi: 10.1111/ajco.12457. Epub 2016 Feb 29.

PMID:
26923110
14.

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA.

Cancer Discov. 2015 Sep;5(9):920-31. doi: 10.1158/2159-8290.CD-15-0125. Epub 2015 Jun 17.

15.

Clinical implications of genomics for cancer risk genetics.

Thomas DM, James PA, Ballinger ML.

Lancet Oncol. 2015 Jun;16(6):e303-8. doi: 10.1016/S1470-2045(15)70026-4. Epub 2015 May 27.

PMID:
26065615
16.

Surveillance recommendations for patients with germline TP53 mutations.

Ballinger ML, Mitchell G, Thomas DM.

Curr Opin Oncol. 2015 Jul;27(4):332-7. doi: 10.1097/CCO.0000000000000200. Review.

PMID:
26049273
17.

Timing and context: important considerations in the return of genetic results to research participants.

McBride KA, Hallowell N, Tattersall MH, Kirk J, Ballinger ML, Thomas DM, Mitchell G, Young MA.

J Community Genet. 2016 Jan;7(1):11-20. doi: 10.1007/s12687-015-0231-7. Epub 2015 May 26.

18.

Etiologic, environmental and inherited risk factors in sarcomas.

Thomas DM, Ballinger ML.

J Surg Oncol. 2015 Apr;111(5):490-5. doi: 10.1002/jso.23809. Epub 2014 Oct 21. Review.

PMID:
25335907
19.

Li-Fraumeni syndrome: cancer risk assessment and clinical management.

McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G.

Nat Rev Clin Oncol. 2014 May;11(5):260-71. doi: 10.1038/nrclinonc.2014.41. Epub 2014 Mar 18. Review.

PMID:
24642672
20.

High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.

Mitchell G, Ballinger ML, Wong S, Hewitt C, James P, Young MA, Cipponi A, Pang T, Goode DL, Dobrovic A, Thomas DM; International Sarcoma Kindred Study.

PLoS One. 2013 Jul 22;8(7):e69026. doi: 10.1371/journal.pone.0069026. Print 2013.

21.

Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells.

Little PJ, Rostam MA, Piva TJ, Getachew R, Kamato D, Guidone D, Ballinger ML, Zheng W, Osman N.

J Pharm Pharmacol. 2013 Jul;65(7):1055-63. doi: 10.1111/jphp.12064. Epub 2013 Apr 24.

PMID:
23738733
22.

Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans.

Osman N, Grande-Allen KJ, Ballinger ML, Getachew R, Marasco S, O'Brien KD, Little PJ.

Cardiovasc Pathol. 2013 Mar-Apr;22(2):146-55. doi: 10.1016/j.carpath.2012.07.002. Epub 2012 Sep 21.

23.

Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFβ receptor phosphorylation.

Little PJ, Getachew R, Rezaei HB, Sanchez-Guerrero E, Khachigian LM, Wang H, Liao S, Zheng W, Ballinger ML, Osman N.

Arch Biochem Biophys. 2012 Sep 1;525(1):25-31. doi: 10.1016/j.abb.2012.05.025. Epub 2012 Jun 7.

PMID:
22683649
24.

An increased incidence of Hodgkin's lymphoma in patients with adult-onset sarcoma.

Downing ME, Dite GS, Ballinger ML; International Sarcoma Kindred Study Consortium.

Clin Sarcoma Res. 2012 Jan 9;2(1):1. doi: 10.1186/2045-3329-2-1.

25.

PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL.

Getachew R, Ballinger ML, Burch ML, Reid JJ, Khachigian LM, Wight TN, Little PJ, Osman N.

Endocrinology. 2010 Sep;151(9):4356-67. doi: 10.1210/en.2010-0027. Epub 2010 Jul 7.

PMID:
20610572
26.

Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor.

Burch ML, Ballinger ML, Yang SN, Getachew R, Itman C, Loveland K, Osman N, Little PJ.

J Biol Chem. 2010 Aug 27;285(35):26798-805. doi: 10.1074/jbc.M109.092767. Epub 2010 Jun 22.

27.

TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2.

Burch ML, Yang SN, Ballinger ML, Getachew R, Osman N, Little PJ.

Cell Mol Life Sci. 2010 Jun;67(12):2077-90. doi: 10.1007/s00018-010-0315-9. Epub 2010 Mar 7.

PMID:
20213272
28.

Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways.

Cardoso LE, Little PJ, Ballinger ML, Chan CK, Braun KR, Potter-Perigo S, Bornfeldt KE, Kinsella MG, Wight TN.

J Biol Chem. 2010 Mar 5;285(10):6987-95. doi: 10.1074/jbc.M109.088674. Epub 2009 Dec 30.

29.

Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells.

Getachew R, Ballinger ML, Burch ML, Little PJ, Osman N.

Eur J Pharmacol. 2010 Jan 25;626(2-3):186-92. doi: 10.1016/j.ejphar.2009.09.066. Epub 2009 Oct 8.

PMID:
19818754
30.

Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.

Ballinger ML, Osman N, Hashimura K, de Haan JB, Jandeleit-Dahm K, Allen T, Tannock LR, Rutledge JC, Little PJ.

J Cell Mol Med. 2010 Jun;14(6B):1408-18. doi: 10.1111/j.1582-4934.2009.00902.x. Epub 2009 Sep 14.

31.

Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation.

Yang SN, Burch ML, Getachew R, Ballinger ML, Osman N, Little PJ.

Arch Physiol Biochem. 2009 Jul;115(3):147-54. doi: 10.1080/13813450903110754.

PMID:
19580379
32.

Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process.

Little PJ, Ballinger ML, Burch ML, Osman N.

Open Biochem J. 2008;2:135-42. doi: 10.2174/1874091X00802010135. Epub 2008 Nov 18.

33.

Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL.

Ballinger ML, Ivey ME, Osman N, Thomas WG, Little PJ.

Atherosclerosis. 2009 Aug;205(2):451-7. doi: 10.1016/j.atherosclerosis.2009.01.024. Epub 2009 Jan 24.

PMID:
19217622
34.

p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis.

Osman N, Ballinger ML, Dadlani HM, Getachew R, Burch ML, Little PJ.

Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):287-92. Review.

PMID:
19075640
35.

Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding.

Ballinger ML, Osman N, Wilks AF, Su S, Burns CJ, Bu X, Little PJ.

J Cardiovasc Pharmacol. 2008 Nov;52(5):403-12. doi: 10.1097/FJC.0b013e31818a8907.

PMID:
19033819
36.

Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.

Little PJ, Ballinger ML, Survase S, Osman N, Ogru E, Geytenbeek S, Bruemmer D, Nigro J.

J Cardiovasc Pharmacol. 2008 Mar;51(3):274-9. doi: 10.1097/FJC.0b013e3181626ce7.

PMID:
18356692
37.

Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle.

Dadlani H, Ballinger ML, Osman N, Getachew R, Little PJ.

J Biol Chem. 2008 Mar 21;283(12):7844-52. doi: 10.1074/jbc.M703125200. Epub 2008 Jan 25.

38.

Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis.

Little PJ, Ballinger ML, Osman N.

Vasc Health Risk Manag. 2007;3(1):117-24. Review.

39.

Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease.

Grande-Allen KJ, Osman N, Ballinger ML, Dadlani H, Marasco S, Little PJ.

Cardiovasc Res. 2007 Oct 1;76(1):19-28. Epub 2007 May 17. Review.

PMID:
17560967
40.

Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents.

de Dios ST, Frontanilla KV, Nigro J, Ballinger ML, Ivey ME, Cawson EA, Little PJ.

J Diabetes Complications. 2007 Mar-Apr;21(2):108-17.

PMID:
17331859
41.

Glycated and carboxy-methylated proteins do not directly activate human vascular smooth muscle cells.

Ballinger ML, Thomas MC, Nigro J, Ivey ME, Dilley RJ, Little PJ.

Kidney Int. 2005 Dec;68(6):2756-65.

42.

New approaches to regulating the chondroitin/dermatan sulfate glycosaminoglycan component of the vascular extracellular matrix.

Nigro J, Ballinger ML, Survase S, Osman N, Little PJ.

ScientificWorldJournal. 2005 Jul 12;5:515-20. Review. No abstract available.

43.

Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding.

Nigro J, Ballinger ML, Dilley RJ, Jennings GL, Wight TN, Little PJ.

Diabetologia. 2004 Dec;47(12):2105-13. Epub 2004 Dec 9.

PMID:
15592811
44.

Regulation of glycosaminoglycan structure and atherogenesis.

Ballinger ML, Nigro J, Frontanilla KV, Dart AM, Little PJ.

Cell Mol Life Sci. 2004 Jun;61(11):1296-306. Review.

PMID:
15170508
45.

Structural changes at cut ends of earthworm giant axons in the interval between dye barrier formation and neuritic outgrowth.

Lichstein JW, Ballinger ML, Blanchette AR, Fishman HM, Bittner GD.

J Comp Neurol. 2000 Jan 10;416(2):143-57.

PMID:
10581462
46.

Calcium entry initiates processes that restore a barrier to dye entry in severed earthworm giant axons.

Blanchette AR, Ballinger ML, Fishman HM, Bittner GD.

Neurosci Lett. 1999 Sep 17;272(3):147-50.

PMID:
10505602
47.

Rapid induction of functional and morphological continuity between severed ends of mammalian or earthworm myelinated axons.

Lore AB, Hubbell JA, Bobb DS Jr, Ballinger ML, Loftin KL, Smith JW, Smyers ME, Garcia HD, Bittner GD.

J Neurosci. 1999 Apr 1;19(7):2442-54.

48.

Heat-shock proteins in axoplasm: high constitutive levels and transfer of inducible isoforms from glia.

Sheller RA, Smyers ME, Grossfeld RM, Ballinger ML, Bittner GD.

J Comp Neurol. 1998 Jun 22;396(1):1-11.

PMID:
9623883
49.

Endocytotic formation of vesicles and other membranous structures induced by Ca2+ and axolemmal injury.

Eddleman CS, Ballinger ML, Smyers ME, Fishman HM, Bittner GD.

J Neurosci. 1998 Jun 1;18(11):4029-41.

50.

Delaminating myelin membranes help seal the cut ends of severed earthworm giant axons.

Ballinger ML, Blanchette AR, Krause TL, Smyers ME, Fishman HM, Bittner GD.

J Neurobiol. 1997 Dec;33(7):945-60.

PMID:
9407015

Supplemental Content

Loading ...
Support Center